Related Experiment Video

Updated: May 21, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Usefulness of insulin detemir in Japanese children with type 1 diabetes

Kazuhiko Jinno1, Tatsuhiko Urakami, Reiko Horikawa

  • 1Department of Pediatrics, West Japan Railway Company Hiroshima General Hospital, Hiroshima, Japan.

Pediatrics International : Official Journal of the Japan Pediatric Society
|June 26, 2012
PubMed

Insights

Insulin detemir effectively manages diabetes in Japanese youth, showing significant improvements in HbA1c and fasting blood glucose. This basal insulin is safe and well-tolerated for pediatric diabetes care.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Observational study on insulin detemir efficacy and safety in Japanese children and adolescents.
  • Focus on diabetes management in a pediatric population.

Purpose of the Study:

  • Investigate the efficacy and safety of insulin detemir (detemir) for diabetes management.
  • Evaluate detemir's role in basal-bolus therapy for Japanese children and adolescents.

Main Methods:

  • Analysis of data from the Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes database.
  • Inclusion of 90 children switching to detemir basal-bolus therapy, observed for at least 12 months.
  • Assessment of hemoglobin A1c (HbA1c), fasting blood glucose (FBG), and hypoglycemia frequency.

Main Results:

  • Significant reductions in HbA1c and FBG observed at 3 and 6 months post-switch to detemir.
  • Subset analysis revealed sustained HbA1c reductions, considering seasonal variations.
  • Low incidence of severe hypoglycemia (4.4 episodes per 100 patient-years) during detemir treatment.

Conclusions:

  • Insulin detemir demonstrates effectiveness and safety as a basal insulin.
  • Supports the use of detemir for managing diabetes in Japanese pediatric patients.
  • Highlights the potential for improved glycemic control and safety in this population.
Abstract

More Related Videos

Fat-Covered Islet Transplantation Using Epididymal White Adipose Tissue06:39

Fat-Covered Islet Transplantation Using Epididymal White Adipose Tissue

Published on: May 25, 2021

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...